Worcester-based Biovest International Inc. will file and seek conditional approval from the FDA of its therapeutic anti-cancer vaccine, Biovax ID, for the indication of follicular Non-Hodgkin’s Lymphoma.
If conditionally approved by the target date of mid-June 2008, Biovest, a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., would begin commercial sales and marketing by early 2009, the company said.
The company said it intends to file separate applications with the FDA and its European counterpart, the European Medicines Agency.
